Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
Completed
Zealand Pharma
Phase 1
The primary objective of the trial is to characterize the pharmacokinetic (PK) profiles of
glepaglutide and its primary active metabolites following once-daily and once-weekly
subcutaneous (SC) injections and after a single intravenous (IV) infusion in healthy
subjects.
Glepaglutide is a proposed International Nonproprietary Name for ZP1848
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Recruiting
Zealand Pharma
Phase 3
The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing
parenteral support volume in patients with short bowel syndrome.
Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Recruiting
Zealand Pharma
Phase 3
The primary objective of the trial is to evaluate the long-term safety of glepaglutide
treatment in patients with short bowel syndrome (SBS).
Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
Completed
Zealand Pharma
Phase 1
This is two stage design, open-label, multi-center, non-randomized trial evaluating the PK of
a single, subcutaneous dose of 10 mg glepaglutide in subjects with varying degrees of renal
function. The renal function will be calculated by the estimated glomerular filtration rate
(eGFR) according to the Modification of Diet in Renal Disease (MDRD) equation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
